Table of Contents
International Journal of Proteomics
Volume 2010, Article ID 964251, 9 pages
http://dx.doi.org/10.1155/2010/964251
Research Article

Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders

1School of Molecular and Microbial Biosciences, University of Sydney, Sydney, NSW 2006, Australia
2Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia

Received 17 December 2009; Accepted 15 February 2010

Academic Editor: Peter Nilsson

Copyright © 2010 Carlos Cassano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Baran-Marszak, J. Feuillard, I. Najjar et al., “Differential roles of STAT1a and STAT1ß in fludarabine-induced cell cycle arrest and apoptosis in human B cells,” Blood, vol. 104, no. 8, pp. 2475–2483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. C. S. Tam, M. Wolf, H. M. Prince et al., “Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma,” Cancer, vol. 106, no. 11, pp. 2412–2420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Nabhan, R. B. Gartenhaus, and M. S. Tallman, “Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era,” Leukemia Research, vol. 28, no. 5, pp. 429–442, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Hagenbeek, H. Eghbali, S. Monfardini et al., “Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV Low-grade malignant non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 24, no. 10, pp. 1590–1596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Blum, J. L. Johnson, D. Niedzwiecki et al., “Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of cancer and leukemia group B study 9153,” Cancer, vol. 107, no. 12, pp. 2817–2825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. K. Wilson, E. Szabados, S. P. Mulligan, and R. I. Christopherson, “Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines,” International Journal of Biochemistry and Cell Biology, vol. 30, no. 7, pp. 833–842, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Marzo, P. Pérez-Galán, P. Giraldo, D. Rubio-Félix, A. Anel, and J. Naval, “Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria,” Biochemical Journal, vol. 359, no. 3, pp. 537–546, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Robak, “Cladribine in the treatment of chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 40, no. 5-6, pp. 551–564, 2001. View at Google Scholar · View at Scopus
  9. C. Rozman and E. Montserrat, “Chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 333, no. 16, pp. 1052–1057, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Kishimoto, H. Kikutani, A. E. G. von dem Borne et al., Leukocyte Typing VI. White Cell Differentiation Antigens, Garland Publishing, New York, NY, USA, 1997.
  11. M. S. Czuczman, A. Thall, T. E. Witzig et al., “Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4390–4398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Robak, “Monoclonal antibodies in the treatment of chronic lymphoid leukemias,” Leukemia and Lymphoma, vol. 45, no. 2, pp. 205–219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Kreitman and I. Pastan, “Immunotoxins in the treatment of hematologic malignancies,” Current Drug Targets, vol. 7, no. 10, pp. 1301–1311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. B. H. Mavromatis and B. D. Cheson, “Novel therapies for chronic lymphocytic leukemia,” Blood Reviews, vol. 18, no. 2, pp. 137–148, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Byrd, K. Rai, B. L. Peterson et al., “Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011,” Blood, vol. 105, no. 1, pp. 49–53, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Keating, S. O'Brien, M. Albitar et al., “Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4079–4088, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Kennedy, A. Rawstron, C. Carter et al., “Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia,” Blood, vol. 99, no. 6, pp. 2245–2247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Robak, P. Smolewski, H. Urbanska-Rys, J. Gora-Tybor, J. Z. Blonski, and M. Kasznicki, “Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies,” Leukemia and Lymphoma, vol. 45, no. 5, pp. 937–944, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Barber, L. Belov, and R. I. Christopherson, “All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias,” Leukemia Research, vol. 32, no. 2, pp. 315–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. L. White, L. Belov, N. Barber, P. D. Hodgkin, and R. I. Christopherson, “Immunophenotypic changes induced on human HL60 leukaemia cells by 1α,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate,” Leukemia Research, vol. 29, no. 10, pp. 1141–1151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Stacchini, M. Aragno, A. Vallario et al., “MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation,” Leukemia Research, vol. 23, no. 2, pp. 127–136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Epstein, B. G. Achong, Y. M. Barr, B. Zajac, G. Henle, and W. Henle, “Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji),” Journal of the National Cancer Institute, vol. 37, no. 4, pp. 547–559, 1966. View at Google Scholar · View at Scopus
  23. L. Belov, S. P. Mulligan, N. Barber et al., “Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray,” British Journal of Haematology, vol. 135, no. 2, pp. 184–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Brugiatelli, B. Holowiecka, A. Dmoszynska et al., “2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience,” Annals of Hematology, vol. 73, no. 2, pp. 79–84, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Robak, “Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies,” Transfusion and Apheresis Science, vol. 32, no. 1, pp. 33–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Morabito, M. Mangiola, D. Rapezzi et al., “Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro,” Haematologica, vol. 88, no. 8, pp. 864–873, 2003. View at Google Scholar · View at Scopus
  27. G. Cutrona, N. Leanza, M. Ulivi et al., “Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo,” Blood, vol. 94, no. 9, pp. 3067–3076, 1999. View at Google Scholar · View at Scopus
  28. L. Ginaldi, M. De Martinis, E. Matutes, N. Farahat, R. Morilla, and D. Catovsky, “Levels of expression of CD19 and CD20 in chronic B cell leukaemias,” Journal of Clinical Pathology, vol. 51, no. 5, pp. 364–369, 1998. View at Google Scholar · View at Scopus
  29. T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling, “Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity,” Clinical Cancer Research, vol. 12, no. 13, pp. 4027–4035, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Schulz, S. K. Klein, U. Rehwald et al., “Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia,” Blood, vol. 100, no. 9, pp. 3115–3120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Di Gaetano, Y. Xiao, E. Erba et al., “Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone,” British Journal of Haematology, vol. 114, no. 4, pp. 800–809, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Coleman, D. M. Goldenberg, A. B. Siegel et al., “Epratuzumab: targeting B-cell malignancies through CD22,” Clinical Cancer Research, vol. 9, no. 10, part 2, pp. 3991S–3994S, 2003. View at Google Scholar · View at Scopus
  33. K. M. Haas, S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder, “CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo,” Journal of Immunology, vol. 177, no. 5, pp. 3063–3073, 2006. View at Google Scholar · View at Scopus
  34. M. A. Santana, G. Pedraza-Alva, N. Olivares-Zavaleta et al., “CD43-mediated signals induce DNA binding activity of AP-1, NF-AT and NF?B transcription factors in human T lymphocytes,” The Journal of Biological Chemistry, vol. 275, no. 40, pp. 31460–31468, 2000. View at Google Scholar · View at Scopus
  35. L. Kadaja, S. Laos, and T. Maimets, “Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF,” Oncogene, vol. 23, no. 14, pp. 2523–2530, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. W. S. Park, J. S. Chae, K. C. Jung, W. J. Choi, M.-C. Kook, and Y. Bae, “Production and the characterization of monoclonal antibody against CD43, K06,” Tissue Antigens, vol. 63, no. 1, pp. 46–53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Cermak, S. Simova, A. Pintzas, V. Horejsi, and L. Andera, “Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells: roles of transcription, Daxx expression, and adhesion molecules,” The Journal of Biological Chemistry, vol. 277, no. 10, pp. 7955–7961, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. T. J. Brown, W. W. Shuford, W.-C. Wang et al., “Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells,” The Journal of Biological Chemistry, vol. 271, no. 44, pp. 27686–27695, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Gu, L.-P. Dao, and J. Wiley, “Impaired transendothelial migration of B-CLL lymphocytes: a defect linked to low L-selectin expression,” Leukemia and Lymphoma, vol. 42, no. 1-2, pp. 5–12, 2001. View at Google Scholar · View at Scopus
  40. L. E. Van den Hove, S. W. Van Gool, P. Vandenberghe et al., “CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules,” Leukemia, vol. 11, no. 4, pp. 572–580, 1997. View at Google Scholar · View at Scopus
  41. S. Suvas, V. Singh, S. Sahdev, H. Vohra, and J. N. Agrewala, “Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma,” The Journal of Biological Chemistry, vol. 277, no. 10, pp. 7766–7775, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. F. A. Vyth-Dreese, H. Boot, T. A. M. Dellemijn et al., “Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma,” Immunology, vol. 94, no. 4, pp. 580–586, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. A. B. Gottlieb, S. Kang, K. G. Linden et al., “Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis,” Clinical Immunology, vol. 111, no. 1, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Friesen, S. Fulda, and K.-M. Debatin, “Cytotoxic drugs and the CD95 pathway,” Leukemia, vol. 13, no. 11, pp. 1854–1858, 1999. View at Google Scholar · View at Scopus
  45. Y. Nomura, O. Inanami, K. Takahashi, A. Matsuda, and M. Kuwabara, “2-Chloro-2-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4,” Leukemia, vol. 14, no. 2, pp. 299–306, 2000. View at Google Scholar · View at Scopus
  46. V. A. Rao and W. Plunkett, “Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine,” Clinical Cancer Research, vol. 9, no. 8, pp. 3204–3212, 2003. View at Google Scholar · View at Scopus
  47. K. A. Karlsson, M. Stromberg, V. Jonsson, S. P. Mulligan, J. L. Lilienmark, and G. Juliusson, “Cladribine gives longer responce duration than fludarabine and high-dose intermittent chlorambucil as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from international randomized Phase II trial,” Blood, vol. 110, no. 11, 2007, abstract no. 630. View at Google Scholar